Published in final edited form as:

Neurobiol Aging. 2019 March ; 75: 42–50. doi:10.1016/j.neurobiolaging.2018.10.011.

Effect of Apolipoprotein E4 on clinical, neuroimaging and biomarker measures in non-carrier participants in the Dominantly Inherited Alzheimer Network

Aurlie Bussy^{#1,5}, B. Joy Snider^{#1}, Dean Coble², Chengjie Xiong², Anne M. Fagan¹, Carlos Cruchaga³, Tammie L.S. Benzinger⁴, Brian A. Gordon⁴, Jason Hassenstab¹, Randall J. Bateman¹, and John C. Morris¹ **Dominantly Inherited Alzheimer Network**

Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO USA

¹-Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660 S. Euclid, Saint Louis, MO 63110

²-Division of Biostatistics, Washington University School of Medicine, Campus Box 8067, 660 S. Euclid, Saint Louis, MO 63110

³-Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 660 S. Euclid, Saint Louis, MO 63110

⁴-Department of Radiology, Washington University School of Medicine, Campus Box 8131, 660 S. Euclid, Saint Louis, MO 63110

⁵-Current affiliation: McGill University/Douglas Mental Health University Institute, Montreal, Quebec, Canada

These authors contributed equally to this work.

Abstract

The apolipoprotein E ϵ 4 allele (*APOE4*) is the major genetic risk factor for sporadic Alzheimer Disease (AD). *APOE4* may have effects on cognition and brain atrophy years before the onset of symptomatic AD. We analyzed the effects of *APOE4* in a unique cohort of young adults who had undergone comprehensive assessments as part of the Dominantly Inherited Alzheimer Network (DIAN), an international longitudinal study of individuals from families with Autosomal Dominant AD. We analyzed the effect of an *APOE4* allele on cognitive measures, volumetric MRI, amyloid deposition, glucose metabolism and on cerebrospinal fluid levels of AD biomarkers in 162 participants that did not carry the mutant gene (non-carriers). *APOE4*⁺ and *APOE4*[−] mutation non-carriers had similar performance on cognitive measures. Amyloid deposition began

Corresponding author: B. Joy Snider, MD, PhD, Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660 S. Euclid, Saint Louis, MO 63110 (sniderj@wustl.edu).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosure

The authors have no actual or potential conflicts of interest.

at an earlier age in *APOE4*+ participants, while hippocampal volume was similar between the groups. These preliminary findings are consistent with growing evidence that the *APOE4* allele may exert effects in mid-life years before symptom onset, promoting amyloid deposition before altering cognitive performance or brain structure.

Keywords

Alzheimer disease; *APOE*; Autosomal Dominant; Amyloid Precursor Protein; Presenilin 1; Presenilin 2; Biomarkers

Introduction

Alzheimer disease (AD), the most common age-related progressive neurodegenerative disorder, typically becomes symptomatic in people older than age 65 (late onset AD, LOAD); less commonly, symptom onset may be earlier. People with the much less common autosomal dominant form of AD (ADAD¹) typically develop symptoms at an early age, generally before age 60 and as early as the third decade of life (e.g., Snider et al., 2005). The Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) began in 2008 with funding from the National Institute of Aging (NIA). This international multicenter study supports the collection of longitudinal clinical, cognitive and biomarker data and tissue from over 500 ADAD families worldwide (Morris et al., 2012). Importantly, family members are enrolled in ADAD whether or not they carry the ADAD-causing mutation. Only 17% of DIAN participants do know their mutation status, so many mutation noncarriers (NCs) participate in the study and undergo the same evaluations as mutation carriers, providing a unique cohort in which clinical, cognitive and biomarker assessments are available in cognitively normal young adults.

Although the details of the pathogenic cascade that lead to AD are still under investigation, many studies have demonstrated a consistent pattern of changes in molecular biomarkers in both sporadic AD and ADAD; these changes may begin 20-25 years before the onset of symptoms. The DIAN study has been useful in this regard (Bateman et al., 2012; Benzinger et al., 2013; Cash et al., 2013; Fagan et al., 2014; Wang et al., 2015), as have large cohorts in sporadic AD, including the Alzheimer Disease Neuroimaging Initiative (ADNI, reviewed in Weiner et al., 2017), the Knight Alzheimer Disease Research Center (Fagan et al., 2009; Morris et al., 2009; Vos et al., 2013) and several others (Epelbaum et al., 2017). The results of most, but not all, studies have been consistent with the amyloid hypothesis, demonstrating a temporal sequence with initial changes in the levels of amyloid beta peptide in cerebrospinal fluid (CSF), followed by changes in positron emission tomography (PET) amyloid imaging, then alterations in hippocampal volume, glucose metabolism and CSF tau, and then subtle cognitive changes. Symptomatic onset occurs ~20 years after the first

¹Abbreviations used: Alzheimer Disease Neuroimaging Initiative (ADNI), amyloid beta peptide 1-42 (A β ₄₂), Amyloid precursor protein (APP), analysis of covariance (ANCOVA), apolipoprotein E (APOE), Autosomal dominant Alzheimer disease (ADAD), cerebrospinal fluid (CSF), Clinical Dementia Rating (CDR), Dominantly Inherited Alzheimer Network observational study (DIAN-OBS), fluorodeoxyglucose (FDG), magnetic resonance imaging (MRI), Mini-Mental State Exam (MMSE), non-carriers (NC), Pittsburgh Compound B (PiB), positron emission tomography (PET), presenilin 1 (PSEN1), presenilin 2 (PSEN2), regions of interest (ROIs), standardized uptake value ratios (SUVs)

detection of changes in amyloid (Bateman et al., 2012; Jack et al., 2010). Some studies have suggested that cognitive performance early in life, decades before changes in amyloid biomarkers, can predict subsequent risk for symptomatic AD in late life. For example, the Nun Study (Riley et al., 2005) demonstrated a relationship between idea density in the second and third decades of life and presence of neuropathological AD in late life, suggesting that risk for AD or even AD pathogenic cascades may begin early in the life span.

The $\epsilon 4$ allele of *apolipoprotein E* (*APOE4*) remains the major genetic risk factor for sporadic AD (Burke and Roses, 1991; Corder et al., 1993; Strittmatter et al., 1993). Individuals homozygous for the $\epsilon 4$ allele have a greater than 10-fold higher risk of developing AD than those without an $\epsilon 4$ allele, although this effect is stronger in Caucasians than in Hispanics or African Americans (Farrer et al., 1997). *APOE* has two other isoforms: *APOE3* and *APOE2*; the *APOE2* allele may reduce the risk of AD (Talbot et al., 1994). The $\epsilon 4$ allele is associated with higher risk of both early-onset and late-onset sporadic AD, age-related cognitive impairment, and with cardiovascular disease and type 2 diabetes (El-Lebedy et al., 2016). The *APOE4* allele can also accelerate development of cortical A β deposition and decreases in CSF A β_{42} levels in individuals who have ADAD (Lim et al., 2016), as well as in sporadic cases (Grimmer et al., 2010; Jack et al., 2013; Morris et al., 2010; Villemagne et al., 2011).

The aim of this study was to look at the effect of *APOE4* genotype on clinical, cognitive and biomarker measures in the young cohort recruited for the DIAN-OBS study, specifically focusing on those participants who did not carry an ADAD-causing mutation. We hypothesized that in these young NC DIAN-OBS participants, the presence of an *APOE4* allele would affect brain structure and AD biomarkers in individuals many years prior to the possible development of AD symptoms.

Material and Methods

Participants

All participants in the DIAN-OBS study have a parent or consanguineous relative with a known mutation causing symptomatic AD. Participants enrolled in the DIAN-OBS participate in all assessments whether or not they carry the ADAD-causing mutation that affects their family. Participants are enrolled in the DIAN-OBS study at 1 of 20 current international study sites and undergo uniform longitudinal assessments including clinical, cognitive, genetic, neuroimaging and fluid biomarker measures (Morris et al., 2012; Moulder et al., 2013). For this analysis, we included baseline assessments from 162 DIAN-OBS participants who had study visits between February 9, 2009 and June 21, 2016 and who met the inclusion criteria, which included 1) confirmed as not having an ADAD causing mutation (NC), 2) normal cognition, defined as having a Clinical Dementia rating (CDR) of 0, 3) having one or zero *APOE4* alleles and 4) having clinical and cognitive testing, and 5) completed biomarker studies including PET amyloid imaging with [^{11}C]Pittsburgh Compound B Pittsburgh Compound B (PET-PiB), glucose imaging with [^{18}F] Fluorodeoxyglucose (FDG-PET), magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) levels of AD biomarkers amyloid beta peptide 42 (A β_{42}), total tau and

phosphorylated tau (ptau₁₈₁) from the time-locked semiannual data freeze (DIAN datafreeze 11). All participants provided informed consent for study participation; the study was approved by the Washington University Human Research Protection Office.

Clinical assessments

The Clinical Dementia Rating (CDR) (Morris, 1993) was used for the clinical assessment. Family and medical history and physical and neurological examinations were completed on all participants. Clinicians completing the CDR and clinical assessment were blinded as to mutation status. All participants included in this analysis had a global CDR rating of 0, indicating no cognitive impairment, at the assessment within 1 year of the completion of cognitive, imaging and biomarker measures. Assessments in the DIAN-OBS study are performed every 3 years for participants with normal cognition; data presented here are from the baseline (initial) assessment.

Neuropsychological testing

All participants completed a battery of neuropsychological tests as previously described (Storandt et al., 2014). Measures included tests of semantic memory (category fluency for animals and vegetables and letter fluency), episodic memory (word list recall immediate and delayed, Wechsler Memory Scale (WMS-R) logical memory immediate and delayed), and associative learning (pair binding, with scores reported for correct identification of intact pairs, new pairs and mixed pairs) and tests of processing speed and executive function (Trailmaking Test Parts A and B, Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit Symbol Substitution) and the Mini-Mental State Exam (MMSE).

Brain imaging

Structural brain imaging with MRI: The Alzheimer Disease Neuroimaging Initiative (ADNI) structural MRI protocol (Jack et al., 2008) was used for acquisition. Every site underwent quality control assessment to insure acquisition conformity. A 3-Tesla scanner was used to acquire T1-weighted images (1.1×1.1×1.2 mm voxels). Images were screened by the ADNI imaging core for protocol compliance and artifacts. All MRI sessions were processed using FreeSurfer 5.3 to define cortical and subcortical regions of interest (ROIs). Regional volumes were corrected for head size using a regression approach (Buckner et al., 2004). These ROIs were used for the processing of PET imaging data. We selected the total hippocampal volume for statistical analyses as this region has been shown before to be sensitive to AD pathophysiology (Dickerson et al., 2001; Fox et al., 1996; Gordon et al., 2016).

Metabolic and amyloid imaging with PET: Brain metabolism was analyzed FDG-PET and amyloid was imaged with [¹¹C]Pittsburgh Compound B Pittsburgh Compound B (PiB). To account for differences in spatial resolution across PET scanners, a scanner specific filter was applied to achieve a common spatial resolution (8 mm). Both FDG and PiB were processed using the Freesurfer derived ROIs (Su et al., 2013). Data for both modalities was converted to regional standardized uptake value ratios (SUVRs) using the cerebellar cortex as a reference. A regional spread function technique (Rousset et al., 1998; Su et al., 2015) was used to partial volume correct the data. Global amyloid deposition was summarized

using the average of regions previously shown to be sensitive to AD pathology (Su et al., 2013; Su et al., 2015). Additionally, we examined PiB SUVRs, FDG SUVRs and cortical thickness in the precuneus as this region has been shown to be consistently affected in AD (Benzinger et al., 2013; La Joie et al., 2012).

Biochemical analysis

Cerebrospinal fluid was collected by lumbar puncture in the morning after overnight fasting using standard protocols (Fagan et al., 2014). Levels of A β ₄₂, total tau and tau phosphorylated at threonine 181 (ptau₁₈₁) were measured using a multiplex bead-based immunoassay (AlzBio3, Fujirebio, Ghent, Belgium).

Statistical analysis

We conducted a cross-sectional mixed effects analysis of covariance (ANCOVA) at participant baseline visit to test if clinical, cognitive, imaging, and biomarker variables were different between the *APOE4*[−] and *APOE4*⁺ groups as well as males and females. Family of origin was the random effect. Age was a covariate in the analyses since it is known to be a risk factor for non-carriers. Age was centered in all analyses to the mean of all participants. All tests were conducted at the 95% confidence level (alpha=0.05) using PROC MIXED in SAS 9.4. Raw P values, not corrected for multiple comparisons are provided; given the 23 comparisons performed, no findings were significant when corrected for multiple comparisons.

Results

Demographic characteristics

A total of 162 participants met eligibility criteria. Measures were obtained during a 2-4-day visit to a DIAN-OBS site. In a few cases, PET imaging was not performed during the visit; we excluded any PET data from the analysis if obtained more than 1 year from the other measures. The participants ranged in age from 19 to 69 years; mean age for all participants was 38.77 ± 11.68 years. Overall, there were 60.5 % females and 39.5% males. The most common *APOE* genotype was *APOE3/3*; most of the participants who had an *APOE4* allele were heterozygotes. Because of the limited number of participants with each specific *APOE* genotype, analyses were conducted comparing those with one *APOE4* allele (*APOE4*⁺, 31.0% of the sample) to those who did not have an *APOE4* allele (*APOE4*[−], 69.0% of the sample). As shown in Table 1, *APOE4*⁺ and *APOE4*[−] groups had a similar age and gender distribution, although the *APOE4*[−] group was slightly younger than the *APOE4*⁺ group. There was a similar distribution of males and females in both groups and a similar distribution of ADAD-causing mutations (overall 66.7% were from families with a *PSEN1* mutation; 21.6% from families with an *APP* mutation and 11.7% from families with a *PSEN2* mutation). Note that participants included in this analysis did not themselves carry the ADAD-causing mutation.

Effect of *APOE4* alone on cognitive performance, imaging or biomarker measures

Results of the cognitive, imaging and biomarker measures are shown in Table 2. *APOE4*⁺ and *APOE4*[−] groups performed very similarly on most tests, although the *APOE4*[−] group

generally had slightly superior scores on most cognitive tests. *APOE4*– participants performed slightly but significantly better than *APOE4*+ participants on the MMSE and on one test of associative memory (identification of new/novel pairs on the pair-binding test) and on one of three tests of semantic fluency (category fluency vegetables) but not on two other similar tests (category fluency for animals and a letter fluency test). There were no significant differences between *APOE4*+ and *APOE4*– participants on volumetric MRI measures for the two regions most affected early in Alzheimer disease (precuneus and hippocampus) or in amyloid deposition (measured by binding to [¹¹C]Pittsburgh Compound B Pittsburgh Compound B (PiB)) or on glucose metabolism in the precuneus. There were no differences between *APOE4*+ and *APOE4*– participants in levels of CSF biomarkers of AD pathology (Table 3, below).

Effect of *APOE4* and age on cognitive performance

Since the participants in this cross-sectional study included a broad age range (19-69 years), we included age as a covariate in the analysis. Age did not have an effect on most of the cognitive test scores, with the exception of two speeded tasks, (WAIS-R Digit symbol (Wechsler 1981) and Tralmaking A), where increasing age was associated with slightly poorer scores. Age did not have an effect on category or letter fluency in our sample.

The only significant interactions between age and *APOE4* status on cognitive testing was on the pair binding associative learning tasks (pair binding-mixed). When we looked more closely at the effect of age and *APOE4* status, as shown in Figure 1, we found that older *APOE4*+ participants tended to perform better than younger *APOE4*+ participants, while performance in *APOE4*– was largely stable with age. There were no other significant interactions for age with cognitive performance.

Age-related changes in brain structure and amyloid deposition in *APOE4* carriers and noncarriers

Age was associated with an increase in amyloid deposition in precuneus and in the averaged global amyloid deposition regions (raw $P=0.0022$ and $P=0.0232$ respectively) and with a decline in glucose metabolism in the precuneus ($P=0.0346$). As shown in Figure 2 Panels A and B, there was a significant interaction between age and *APOE4* status on amyloid deposition in both precuneus ($P=0.0024$) and in the pooled cortical regions ($P=0.0209$), with the *APOE4*+ participants having more rapid amyloid accumulation. The slopes began to diverge around 30-40 years of age, but this effect disappeared when we repeated the analysis without including those over the age of 50, so the older members of the cohort are driving this finding. There was no significant interaction between age and *APOE4* for glucose metabolism.

As expected, age was related to MRI volumetric measures, with an age associated decrease in precuneus thickness ($P=0.0022$) and hippocampal volume ($P=0.0232$). There was a significant interaction between age and presence of an *APOE4* allele for hippocampal volume ($P=0.0280$), but this interaction did not achieve statistical significance for precuneus thickness ($P=0.0567$, See Figure 2 C and D). Somewhat surprisingly, the trend was for a

stronger effect of age on precuneus thickness and hippocampal volume in the *APOE4*– group.

Age effects on CSF biomarkers

As expected, there was an effect of age on CSF total tau ($P=.0044$) in all participants, but there was no effect of age on CSF $A\beta_{42}$ or on levels of phosphorylated tau, and no interactions between age and *APOE4* status. As shown in Figure 3, below, tau seemed to increase slowly with age in both *APOE4* groups (Panel A).

Discussion

This study provides a cross-sectional analysis of a robust data set from a unique cohort of 162 cognitively normal adults ranging in age from 19-69 that enables analysis of the effects of one *APOE4* allele on cognitive testing, brain structure and function and biomarkers for Alzheimer disease. This is the first study to include cognitive, fluid and imaging biomarkers in a young cohort. We found that cognitive performance, brain structure and glucose metabolism were very similar between young *APOE4*+ and *APOE4*– individuals. We did not see an effect of *APOE4* on fluid biomarkers, but did observe an increase in amyloid deposition with age as measured by PET imaging.

The lack of an effect of *APOE4* on cognitive performance is consistent with several other reports (Deary et al., 2002; Reiman et al., 2004, 2005; Turic et al., 2001; Wright et al., 2003; Yu et al., 2000), but in contrast to other studies that reported better performance on some measures for *APOE4* carriers in young adults (Alexander et al., 2007; Puttonen et al., 2003). These findings in young adults are in contrast to studies in older adults, where the presence of an *APOE4* allele has been associated with poorer cognitive performance even in the absence of dementia or mild cognitive impairment (reviewed in Wisdom et al., 2011). The association of age with performance on speeded tasks (Trail Making A and B) was consistent with prior studies (Tombaugh, 2004). The interaction between age and the presence of an *APOE4* allele on an associative learning task (pair binding score for mixed pairs) is difficult to interpret given the abnormal distribution of test scores (Figure 1).

We did not see differences in brain structure between *APOE4*+ and *APOE4*– individuals, but our analysis was limited to hippocampal volume and thickness of the precuneus and did not include participants under the age of 19. As expected, increasing age did have an effect on brain structure, with decreases in hippocampal volume and precuneus thickness with age. We did not find more rapid atrophy of brain structures in the *APOE4*+ participants, but instead found the age-related decline in hippocampal volume was more pronounced in the *APOE4*– group (Figure 2D), with a similar trend in the precuneus (Figure 2C). This is in contrast to many studies suggesting more rapid atrophy of these structures in *APOE4*+ participants (Cherbuin et al., 2007) although other studies have had similar findings, showing no significant differences between cognitively normal *APOE4* homozygotes and those without an *APOE4* allele across the lifespan (Habes et al., 2016; Reiman et al., 1998). The average age of cognitively normal participants in those studies was older than the cohort studied here and could have included participants with very mild or not yet symptomatic Alzheimer disease, so it is possible that *APOE4* related atrophy begins later in the AD

pathogenic cascade. Our findings are consistent with a prior report showing that noncarriers of *APOE4* have more pronounced age-related atrophy (Gonneaud et al., 2016). This may also be consistent with the idea that *APOE4* may have an antagonistic pleiotropic effect, with benefits on brain structure early in life. In the largest study to date on the effects of *APOE* alleles on brain structure and cognition in children (Chang et al., 2016), children with an *APOE4* allele (*APOE3/4* heterozygotes) had larger volumes in some brain regions (hippocampi, occipital and frontal cortical areas) than those who were homozygous for *APOE3*.

Some but not all studies have found a significant decrease in glucose metabolism in young adults who carry an *APOE4* allele. Reiman et al. found that glucose metabolism was reduced in frontal, temporal and parietal lobes and in the cingulate cortex in cognitively normal young adults with an *APOE4* allele (Reiman et al., 1996; Reiman et al., 2004, 2005). We observed an association of glucose metabolism with age in the precuneus, but there was no interaction of *APOE4* status with glucose metabolism or with age. This may reflect differences in the cohort or in the areas sampled but we note one other study has also found that *APOE4* does not affect glucose metabolism in cognitively normal adults across the lifespan (Gonneaud et al., 2016).

We did not see differences between *APOE4*⁺ and *APOE4*[−] participants in amyloid deposition in the precuneus or in pooled cortical regions, but we did observe a correlation between amyloid deposition and age and an increased slope of amyloid accumulation with age in *APOE4*⁺ participants (Figure 2A and B). Amyloid deposition in precuneus and in cortex overall was stable with age for *APOE4* noncarriers while *APOE4* carriers had increasing amyloid deposition with age, consistent with prior reports in older cohorts (Liu et al., 2016; Rowe et al., 2010). Our findings suggest that *APOE4* effects on amyloid accumulation may begin relatively early in life, perhaps around age 30-40, consistent with other reports that included a younger cohort (Gonneaud et al., 2016; Gonneaud et al., 2017) and with autopsy studies showing amyloid beta deposition in individuals aged 40-49 who have an *APOE4* allele (Pletnikova et al., 2015). A meta-analysis of 55 studies also suggested that amyloid accumulation in *APOE4*⁺ participants might begin slightly before age 40, although less than 5% of participants in the pooled studies were under the age of 40 (Jansen et al., 2015). Our findings differ somewhat from the recent report by Gonneaud et al. (Gonneaud et al., 2017), who showed a linear increase in florbetapir binding with age in participants aged 20-60 years and only a marginal effect of *APOE4*. The study reported here has a larger sample size (162 young participants here vs 76 in the Gonneaud study) and used [¹¹C] Pittsburgh Compound B (PiB) rather than florbetapir. The suggestion of an interaction between age and *APOE4* differs from the findings of Jack et al. who observed no interaction between age and *APOE4* when looking at amyloidosis in a cohort aged 50-89 (Jack et al., 2014). These results must be interpreted with caution, however, as the increase in amyloid deposition in the *APOE4*⁺ group is not observed when participants over the age of 50 (n=26) are excluded from the analysis, so this finding is driven by the older participants.

We did not see effects of *APOE4* genotype on any of the CSF measures of AD pathology, but did observe a slight increase in CSF tau with increasing age, consistent with some prior

studies (Paternico et al., 2012; Sjogren et al., 2001; Sutphen et al., 2015). Age did not have a significant effect on CSF levels of ptau or A β ₄₂, in contrast to some prior studies (Popp et al., 2010; Shoji et al., 2001; Sjogren et al., 2001). We did not observe an interaction between age and *APOE4* status for CSF levels of A β ₄₂ (Figure 3B); this is in contrast to findings in a much larger pooled cohort study that analyzed 1233 healthy control subjects, 40–84 years old, where *APOE4*⁺ individuals had higher CSF tau and lower A β ₄₂, starting in their 40s (Toledo et al., 2015).

This study has several limitations. Due to sample size considerations, no measures achieved significance when corrected for multiple comparisons so findings must be considered exploratory. The participants studied here all have family members with an ADAD mutation, so may not reflect the general population. The study is cross-sectional, so lacks longitudinal data. The goal of this exploratory study was to assess all available measures. It will be important to re-assess these findings as longitudinal data becomes available from this cohort.

Our findings overall support the growing literature on the preclinical stages of Alzheimer disease. The exploratory findings here are in line with growing evidence that cerebral amyloid accumulation may begin in middle age, perhaps as early as age 30–40 and that the presence of an *APOE4* allele may accelerate amyloid deposition (Gonneaud et al., 2016; Gonneaud et al., 2017). Changes in CSF A β ₄₂ are thought to precede amyloid deposition, but we did not detect an age or *APOE* dependent effect on CSF A β ₄₂. We did not see effects of *APOE4* on cognitive performance or brain atrophy, making it more likely that the effects of *APOE4* early in disease are associated with amyloid metabolism or deposition. This highlights the need for larger longitudinal studies that include imaging and fluid biomarkers in both young and older adults.

Acknowledgements

Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer's Network (DIAN, UF1AG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study..

References

- Alexander DM, Williams LM, Gatt JM, Dobson-Stone C, Kuan SA, Todd EG, Schofield PR, Cooper NJ, Gordon E, 2007 The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades. *Biological psychology* 75(3), 229–238. [PubMed: 17433528]
- Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, 2012 Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. *N. Engl. J. Med* 367(9), 795–804. [PubMed: 22784036]
- Benzinger TL, Blazey T, Jack CR, Jr., Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, Christensen JJ, Ercole L,

- Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC, 2013 Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* 110(47), E4502–4509. [PubMed: 24194552]
- Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, Snyder AZ, 2004 A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. *Neuroimage* 23(2), 724–738. [PubMed: 15488422]
- Burke JR, Roses AD, 1991 Genetics of Alzheimer's disease. *International journal of neurology* 25-26, 41–51. [PubMed: 11980062]
- Cash DM, Ridgway GR, Liang Y, Ryan NS, Kinnunen KM, Yeatman T, Malone IB, Benzinger TL, Jack CR, Jr., Thompson PM, Ghetti BF, Saykin AJ, Masters CL, Ringman JM, Salloway SP, Schofield PR, Sperling RA, Cairns NJ, Marcus DS, Xiong C, Bateman RJ, Morris JC, Rossor MN, Ourselin S, Fox NC, 2013 The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. *Neurology* 81(16), 1425–1433. [PubMed: 24049139]
- Chang L, Douet V, Bloss C, Lee K, Pritchett A, Jernigan TL, Akshoomoff N, Murray SS, Frazier J, Kennedy DN, Amaral DG, Gruen J, Kaufmann WE, Casey BJ, Sowell E, Ernst T, Pediatric Imaging, N., Genetics Study, C., 2016 Gray matter maturation and cognition in children with different APOE epsilon genotypes. *Neurology* 87(6), 585–594. [PubMed: 27412137]
- Cherbuin N, Leach LS, Christensen H, Anstey KJ, 2007 Neuroimaging and APOE genotype: a systematic qualitative review. *Dement Geriatr Cogn Disord* 24(5), 348–362. [PubMed: 17911980]
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, 1993 Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261(5123), 921–923. [PubMed: 8346443]
- Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, Carothers A, Whalley LJ, 2002 Cognitive change and the APOE epsilon 4 allele. *Nature* 418(6901), 932. [PubMed: 12198535]
- Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L, 2001 MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. *Neurobiol. Aging* 22(5), 747–754. [PubMed: 11705634]
- El-Lebedy D, Raslan HM, Mohammed AM, 2016 Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. *Cardiovascular diabetology* 15, 12. [PubMed: 26800892]
- Epelbaum S, Genthon R, Cavedo E, Habert MO, Lamari F, Gagliardi G, Lista S, Teichmann M, Bakardjian H, Hampel H, Dubois B, 2017 Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. *Alzheimers Dement* 13(4), 454–467. [PubMed: 28188032]
- Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM, 2009 Decreased cerebrospinal fluid Aβ₄₂ correlates with brain atrophy in cognitively normal elderly. *Ann. Neurol* 65(2), 176–183. [PubMed: 19260027]
- Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM, 2014 Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. *Science translational medicine* 6(226), 226–230.
- Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, 1997 Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *J.A.M.A* 278(16), 1349–1356.
- Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, Rossor MN, 1996 Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. *Brain* 119 (Pt 6), 2001–2007. [PubMed: 9010004]
- Gonneaud J, Arenaza-Urquijo EM, Fouquet M, Perrotin A, Fradin S, de La Sayette V, Eustache F, Chetelat G, 2016 Relative effect of APOE epsilon 4 on neuroimaging biomarker changes across the lifespan. *Neurology* 87(16), 1696–1703. [PubMed: 27683850]

- Gonneaud J, Arenaza-Urquijo EM, Mezenge F, Landeau B, Gaubert M, Bejanin A, de Flores R, Wirth M, Tomadesso C, Poisnel G, Abbas A, Desgranges B, Chetelat G, 2017 Increased florbetapir binding in the temporal neocortex from age 20 to 60 years. *Neurology* 89(24), 2438–2446. [PubMed: 29150540]
- Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL, 2016 Longitudinal beta-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. *JAMA neurology* 73(10), 1192–1200. [PubMed: 27548756]
- Grimmer T, Tholen S, Yousefi BH, Alexopoulos P, Forschler A, Forstl H, Henriksen G, Klunk WE, Mathis CA, Perneczky R, Sorg C, Kurz A, Drzezga A, 2010 Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. *Biol Psychiatry* 68(10), 879–884. [PubMed: 20598287]
- Habes M, Toledo JB, Resnick SM, Doshi J, Van der Auwera S, Erus G, Janowitz D, Hegenscheid K, Homuth G, Volzke H, Hoffmann W, Grabe HJ, Davatzikos C, 2016 Relationship between APOE Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort. *AJNR Am J Neuroradiol* 37(9), 1636–1642. [PubMed: 27173368]
- Jack CR, Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, J LW, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, Green R, Bartzokis G, Glover G, Mugler J, Weiner MW, 2008 The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *J Magn Reson Imaging* 27(4), 685–691. [PubMed: 18302232]
- Jack CR, Jr., Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, Pankratz VS, Senjem ML, Gunter JL, Mielke MM, Lowe VJ, Boeve BF, Petersen RC, 2013 Brain beta-amyloid load approaches a plateau. *Neurology* 80(10), 890–896. [PubMed: 23446680]
- Jack CR, Jr., Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, Pankratz VS, Vemuri P, Petersen RC, 2014 Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. *Lancet Neurol* 13(10), 997–1005. [PubMed: 25201514]
- Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ, 2010 Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurology* 9(1), 119–128. [PubMed: 20083042]
- Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Forster S, Fortea J, Fosskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gomez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Kohler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleo A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonca A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Mollergard HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodriguez-Rodriguez E, Roe CM, Rot U, Rowe CC, Ruther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schroder J, Schutte C, Seo SW, Soetewey F, Soininen H, Spuru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenbergh R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin AK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H, 2015 Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *J.A.M.A.* 313(19), 1924–1938.
- La Joie R, Perrotin A, Barre L, Hommet C, Mezenge F, Ibazene M, Camus V, Abbas A, Landeau B, Guilloteau D, de La Sayette V, Eustache F, Desgranges B, Chetelat G, 2012 Region-specific

hierarchy between atrophy, hypometabolism, and beta-amyloid (A β) load in Alzheimer's disease dementia. *J. Neurosci* 32(46), 16265–16273. [PubMed: 23152610]

- Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer, N., 2016 BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. *Brain* 139(Pt 10), 2766–2777. [PubMed: 27521573]
- Liu Y, Tan L, Wang HF, Liu Y, Hao XK, Tan CC, Jiang T, Liu B, Zhang DQ, Yu JT, Alzheimer's Disease Neuroimaging, I., 2016 Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum. *Mol Neurobiol* 53(7), 4539–4547. [PubMed: 26298664]
- Morris JC, 1993 The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* 43(11), 2412–2414.
- Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD, 2012 Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. *Clinical investigation* 2(10), 975–984. [PubMed: 23139856]
- Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA, 2009 Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease. *Archives of Neurology* 66(12), 1469–1475. [PubMed: 20008650]
- Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA, 2010 APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann. Neurol* 67(1), 122–131. [PubMed: 20186853]
- Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, Morris JC, 2013 Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. *Alzheimer's research & therapy* 5(5), 48.
- Paternico D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB, 2012 Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. *Alzheimers Dement* 8(6), 520–527. [PubMed: 22677492]
- Pletnikova O, Rudow GL, Hyde TM, Kleinman JE, Ali SZ, Bharadwaj R, Gangadeen S, Crain BJ, Fowler DR, Rubio AI, Troncoso JC, 2015 Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age. *Cogn Behav Neurol* 28(3), 144–152. [PubMed: 26413742]
- Popp J, Lewczuk P, Frommann I, Kolsch H, Kornhuber J, Maier W, Jessen F, 2010 Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEepsilon4 genotype. *J Alzheimers Dis* 22(2), 459–468. [PubMed: 21084733]
- Puttonen S, Elovainio M, Kivimaki M, Lehtimaki T, Keltikangas-Jarvinen L, 2003 The combined effects of apolipoprotein E polymorphism and low-density lipoprotein cholesterol on cognitive performance in young adults. *Neuropsychobiology* 48(1), 35–40. [PubMed: 12886039]
- Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D, 1996 Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. *N. Engl. J. Med* 334(12), 752–758. [PubMed: 8592548]
- Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J, 2004 Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *Proc. Natl. Acad. Sci. USA* 101(1), 284–289. [PubMed: 14688411]
- Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J, 2005 Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. *Proc. Natl. Acad. Sci. USA* 102(23), 8299–8302. [PubMed: 15932949]
- Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, de Leon MJ, De Santi S, Convit A, Osborne D, Weaver A, Thibodeau SN, 1998 Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. *Ann. Neurol* 44(2), 288–291. [PubMed: 9708558]

- Riley KP, Snowden DA, Desrosiers MF, Markesbery WR, 2005 Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. *Neurobiol. Aging* 26(3), 341–347. [PubMed: 15639312]
- Rousset OG, Ma Y, Evans AC, 1998 Correction for partial volume effects in PET: principle and validation. *J Nucl Med* 39(5), 904–911. [PubMed: 9591599]
- Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Frapp J, Tochon-Danguy H, Morandau L, O’Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL, 2010 Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. *Neurobiol. Aging* 31(8), 1275–1283. [PubMed: 20472326]
- Shoji M, Kanai M, Matsubara E, Tomidokoro Y, Shizuka M, Ikeda Y, Ikeda M, Harigaya Y, Okamoto K, Hirai S, 2001 The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently. *Neurobiol. Aging* 22(2), 209–215. [PubMed: 11182470]
- Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbacke M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nagga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K, 2001 Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. *Clin Chem* 47(10), 1776–1781. [PubMed: 11568086]
- Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, Lendon CL, Goate AM, McKeel DW, Jr., Morris JC, 2005 Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. *Arch Neurol* 62(12), 1821–1830. [PubMed: 16344340]
- Storandt M, Balota DA, Aschenbrenner AJ, Morris JC, 2014 Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). *Neuropsychology* 28(1), 19–29. [PubMed: 24219606]
- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD, 1993 Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 90(5), 1977–1981. [PubMed: 8446617]
- Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, Bateman RJ, Cairns NJ, Aldea P, Cash L, Christensen JJ, Friedrichsen K, Hornbeck RC, Farrar AM, Owen CJ, Mayeux R, Brickman AM, Klunk W, Price JC, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Schofield PR, Buckles V, Morris JC, Benzinger TL, 2015 Partial volume correction in quantitative amyloid imaging. *Neuroimage* 107, 55–64. [PubMed: 25485714]
- Su Y, D’Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, Blazey TM, Christensen JJ, Vora S, Morris JC, Mintun MA, Benzinger TL, 2013 Quantitative analysis of PiB-PET with FreeSurfer ROIs. *PLoS ONE* 8(11), e73377. [PubMed: 24223109]
- Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM, 2015 Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. *JAMA neurology* 72(9), 1029–1042. [PubMed: 26147946]
- Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A, 1994 Protection against Alzheimer’s disease with apoE epsilon 2. *Lancet* 343(8910), 1432–1433.
- Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Tepl S, Moghekar A, Albert M, Hu WT, Monge Argiles JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ, Alzheimer’s Disease Neuroimaging I, 2015 Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects. *Brain* 138(Pt 9), 2701–2715. [PubMed: 26220940]
- Tombaugh TN, 2004 Trail Making Test A and B: normative data stratified by age and education. *Arch Clin Neuropsychol* 19(2), 203–214. [PubMed: 15010086]
- Turic D, Fisher PJ, Plomin R, Owen MJ, 2001 No association between apolipoprotein E polymorphisms and general cognitive ability in children. *Neurosci. Lett* 299(1-2), 97–100. [PubMed: 11166947]
- Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szeke C, Salvado O, Martins R, O’Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe

- CC, 2011 Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. *Ann. Neurol* 69(1), 181–192. [PubMed: 21280088]
- Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Frisoni GB, Froelich L, Nobili F, van der Flier W, Blennow K, Wolz R, Scheltens P, Visser PJ, 2013 Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. *Neurology* 80(12), 1124–1132. [PubMed: 23446677]
- Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, Goate A, Fagan AM, Cairns NJ, Marcus DS, McDade E, Ringman JM, Graff-Radford NR, Ghetti B, Farlow MR, Sperling R, Salloway S, Schofield PR, Masters CL, Martins RN, Rossor MN, Jucker M, Danek A, Forster S, Lane CA, Morris JC, Benzinger TL, Bateman RJ, 2015 Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. *Neurology* 85(9), 790–798. [PubMed: 26245925]
- Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jr., Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ, Alzheimer's Disease Neuroimaging I, 2017 Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. *Alzheimers Dement* 13(4), e1–e85. [PubMed: 28342697]
- Wisdom NM, Callahan JL, Hawkins KA, 2011 The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. *Neurobiol. Aging* 32(1), 63–74. [PubMed: 19285755]
- Wright RO, Hu H, Silverman EK, Tsaih SW, Schwartz J, Bellinger D, Palazuelos E, Weiss ST, Hernandez-Avila M, 2003 Apolipoprotein E genotype predicts 24-month bayley scales infant development score. *Pediatr. Res* 54(6), 819–825. [PubMed: 12930912]
- Yu YW, Lin CH, Chen SP, Hong CJ, Tsai SJ, 2000 Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. *Neurosci. Lett* 294(3), 179–181. [PubMed: 11072144]

Highlights

A single *APOE4* allele does not affect cognitive measures in people aged 19-69.

A single *APOE4* allele does not affect structural or imaging measures in people aged 19-69.

An *APOE4* allele does affect amyloid deposition with age in people aged 19-69.

An *APOE4* allele may accelerate amyloid deposition, possibly beginning as early as the 30-40 years of age.

Figure 1. Changes in performance on pair-binding associative learning task by age and *APOE4* status.

Scores on the mixed item subtest (number of 12 mixed pairs correctly identified) plotted against age. Each circle represents scores from a single participant, with *APOE4*– participants in (blue circles and line) and *APOE4*+ participants (red circles and lines), with age at time of testing on the horizontal axis. The best fit for each group is shown in the solid lines.

Figure 2. Interactions between age and *APOE* status for amyloid deposition and volumetric MRI. Amyloid plaque load as measured by PET-PiB in the precuneus (A) and in an average of six cortical regions (B) plotted over time versus age for *APOE4*- (blue circles and line) and *APOE4*+ (red circles and line) participants. Panel C shows thickness of the precuneus (mm) plotted against age and Panel D shows hippocampal volume (mm³) plotted against age.

Figure 3.

Panel A. CSF total tau levels plotted against age at time of CSF sampling for *APOE4*+ participants (red circles and line) and *APOE4*- participants (blue circles and line). Panel B, CSF Aβ₄₂ levels plotted against age at time of CSF sampling for *APOE4*+ participants (red circles and line) and *APOE4*-participants (blue circles and line).

Table 1:
Demographic features and genotype

The table provides basic demographic information for the sample. Although the participants included here did not have an ADAD-causing mutation, the ADAD-causing mutation in the family is reported as this was included as a random effect in the statistical analysis to account for within and among family variability as families are clustered by mutation.

	<i>APOE4</i> – Mean ± S.D. (range) n=118	<i>APOE4</i> + Mean ± S.D. (range) n=44
Age at clinical assessment (years)	37.18 ± 10.54 (19-66)	43.05 ± 11.38 (19-69)
Female/male (% female)	72/46 (61.0%)	26/18 (59.1%)
<i>APOE</i> genotype distribution	<i>APOE3</i> /3: 100 <i>APOE2</i> /3: 17 <i>APOE2</i> /2: 1	<i>APOE3</i> /4: 44
Family mutation distribution	<i>PSEN1</i> : 81 (68.6%) <i>PSEN2</i> : 11 (9.3%) <i>APP</i> : 26 (22.0%)	<i>PSEN1</i> : 27 (61.4%) <i>PSEN2</i> : 8 (18.2%) <i>APP</i> : 9 (20.4%)

Table 2.
Clinical, cognitive and imaging features by *APOE4* group.

Sample sizes vary by variable because for a variety of reasons not all data were available for every participant . Raw *P* values shown are from the cross-sectional mixed effects analysis of covariance (ANCOVA) to test if clinical, cognitive, imaging, and biomarker variables were different between the *APOE4*– and *APOE4*+ groups, with centered age as a covariate. Values shown in **BOLD** are those that achieved significance ($P < 0.05$) in this exploratory study; note that these are raw *P* values that were not corrected for multiple comparisons; no findings were significant when corrected for the 23 comparisons performed. For cognitive testing, higher scores indicate better performance except for the timed tasks, Trailmaking A and Trailmaking B, where lower scores indicate better performance.

COGNITIVE TEST (range)	<i>APOE4</i> – Mean ±S.D. (range)	n	<i>APOE4</i> + Mean ± S.D. (range)	n	Raw <i>P</i> values		
					<i>APOE4</i> + vs <i>APOE4</i> –	Age	Age and <i>APOE4</i>
MMSE (0-30)	29.1 ± 0.9 (26-30)	117	28.8 ± 1.3 (25-30)	44	0.0209	0.3939	0.3636
Word List recall-immediate (0-16)	6.1 ± 2.0 (1-11)	117	5.6 ± 1.8 (2-9)	44	0.4084	0.3639	0.9033
Word list recall-delayed (0-16)	3.6 ± 2.2 (0-13)	116	3.0 ± 1.9 (0-7)	44	0.7268	0.1501	0.2512
WMS-R Logical Memory-immediate (0-25)	15.3 ± 3.9 (6-24)	117	14.0 ± 4.0 (5-23)	44	0.7268	0.1501	0.2512
WMS-R Logical Memory-delayed (0-25)	14.4 ± 4.1 (3-24)	117	12.9 ± 4.3 (3-22)	44	0.1887	0.4649	0.8343
Pair Binding-mixed (0-12)	8.0 ± 3.0 (1-12)	115	7.4 ± 3.2 (0-12)	43	0.1589	0.5453	0.0341
WAIS-R Digit Symbol (0-93)	61.8 ± 12.2 (35-93)	117	59.9 ± 9.8 (39-83)	43	0.6741	0.0106	0.2288
Trailmaking A (0-150 sec)	21.3 ± 6.0 (11-38)	116	22.8 ± 6.5 (14-48)	44	0.6672	0.0240	0.9616
Trailmaking B (0-300 sec)	57.2 ± 23.0 (28-149)	117	57.3 ± 22.7 (27-125)	44	0.6647	0.1267	0.8079
Category fluency-animals	22.6 ± 5.2 (11-36)	117	21.7 ± 5.3 (10-34)	44	0.3781	0.1750	0.5533
Category fluency-vegetables	15.5 ± 3.5 (4-24)	117	15.0 ± 3.9 (8-28)	44	0.0351	0.5503	0.9651
Category fluency-Letter	39.8 ± 10.8 (15-65)	117	40.1 ± 11.4(24-69)	44	0.3347	0.7210	0.3191
MRI volumes	Mean ±S.D. (range)	n	Mean ±S.D. (range)	n			
Precuneus Thickness (mm)	2.37 ± 0.13 (2.05-2.68)	107	2.36 ± 0.12 (2.12-2.67)	37	0.2154	0.0022	0.0567
Hippocampal Volume mm ³)	8823.1 ± 806.6 (6886.1-10699.5)	110	8740.1 ± 741.6 (6805.2 - 10385.6)	39	0.7104	0.0232	0.0280
PET Measures (SUVR)	Mean ±S.D. (range)	n	Mean ±S.D. (range)	n			
PiB Precuneus	1.12 ± 0.09 (0.89-1.30)	100	1.18 ± 0.15 (0.99-3.12)	35	0.5900	0.0168	0.0024
PiB Global cortical amyloid deposition	1.04 ± 0.07 (0.85-1.21)	100	1.06 ± 0.08 (0.89-1.66)	35	0.7422	0.0227	0.0209
FDG Precuneus	1.89 ± 0.15 (1.51-2.44)	97	1.90 ± 0.17 (1.58-2.44)	35	0.2043	0.0346	0.6904

Table 3.
CSF Measures by *APOE4* group.

Values shown for each group, with 95% confidence intervals. *P* values shown are from the cross-sectional mixed effects analysis of covariance (ANCOVA) to test if clinical, cognitive, imaging, and biomarker variables were different between the *APOE4*– and *APOE4*+ groups, with centered age as a covariate. Values shown in **BOLD** are those that achieved significance ($P < 0.05$).

CSF Measures	<i>APOE4</i> –	n	<i>APOE4</i> +	n	<i>P</i> values		
(pg/ml)	Mean ± S.D. [95% CI]		Mean ± S.D. [95% CI]		<i>APOE4</i> +vs <i>APOE4</i> –	Age	Age and <i>APOE4</i>
Aβ ₄₂ (pg/ml)	448 ± 144 [416 – 478]	89	435 ± 141 [387 – 482]	37	0.7458	0.2418	0.2852
Total Tau (pg/ml)	56 ± 22 [51 – 61]	89	57 ± 25 [49 – 66]	39	0.7526	0.0044	0.6071
Ptau (pg/ml)	29 ± 10 [27 – 31]	89	29 ± 8 [26 – 31]	39	0.4762	0.3777	0.9673